These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 22459893

  • 1. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M, Sumarac Z, Antic D, Bogdanovic A, Elezovic I, Vukosavljevic D, Ignjatovic S, Majkic-Singh N, Suvajdzic N.
    Blood Cells Mol Dis; 2012 Jun 15; 49(1):58-9. PubMed ID: 22459893
    [No Abstract] [Full Text] [Related]

  • 2. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
    Giona F, Palumbo G, Amendola A, Santoro C, Mazzuconi MG.
    J Thromb Haemost; 2006 Aug 15; 4(8):1831-3. PubMed ID: 16879228
    [No Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, Beutler E.
    Trans Assoc Am Physicians; 1991 Aug 15; 104():258-64. PubMed ID: 1845151
    [No Abstract] [Full Text] [Related]

  • 4. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S, Bruno G, Durighello M, Giorgini R, Simeone R, Bembi B.
    Haematologica; 1999 Apr 15; 84(4):376-7. PubMed ID: 10190956
    [No Abstract] [Full Text] [Related]

  • 5. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):119-23. PubMed ID: 20727796
    [Abstract] [Full Text] [Related]

  • 6. Coagulation abnormalities in type 1 Gaucher disease in children.
    Deghady A, Marzouk I, El-Shayeb A, Wali Y.
    Pediatr Hematol Oncol; 2006 Jan 15; 23(5):411-7. PubMed ID: 16728361
    [Abstract] [Full Text] [Related]

  • 7. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
    Elstein D, Abrahamov A, Altarescu G, Zimran A.
    Blood Cells Mol Dis; 2013 Feb 15; 50(2):140. PubMed ID: 23085428
    [No Abstract] [Full Text] [Related]

  • 8. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y, Ali AS.
    J Coll Physicians Surg Pak; 2006 Dec 15; 16(12):786-8. PubMed ID: 17125641
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
    Mitrovic M, Antic D, Elezovic I, Janic D, Miljic P, Sumarac Z, Nikolic T, Suvajdzic N.
    Platelets; 2012 Dec 15; 23(2):143-9. PubMed ID: 21767238
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 15; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 13. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
    Arıkan-Ayyıldız Z, Yuce A, Uslu-Kızılkan N, Demir H, Gurakan F.
    Pediatr Blood Cancer; 2011 Apr 15; 56(4):664-6. PubMed ID: 21298757
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R.
    Blood Cells Mol Dis; 2015 Jan 15; 54(1):9-16. PubMed ID: 25453586
    [Abstract] [Full Text] [Related]

  • 15. Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges.
    Komninaka V, Repa K, Marinakis T, Pouliakis A, Koutsouri T, Tsokanas D, Flevary P, Voskaridou E, Politou M.
    Blood Cells Mol Dis; 2020 Feb 15; 80():102371. PubMed ID: 31670186
    [No Abstract] [Full Text] [Related]

  • 16. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 15; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 17. Enzyme-replacement therapy for Gaucher's disease.
    N Engl J Med; 1991 Dec 19; 325(25):1809-11. PubMed ID: 1944489
    [No Abstract] [Full Text] [Related]

  • 18. Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy.
    Zahran AM, Elsayh KI, El-Deek SE, El-Baz MA.
    Clin Appl Thromb Hemost; 2015 Jan 19; 21(1):58-65. PubMed ID: 23698728
    [Abstract] [Full Text] [Related]

  • 19. [Gaucher disease: enzyme replacement treatment initiated at pediatric age; 20-year experience].
    Vitoria Miñana I, Dalmau Serra J.
    An Pediatr (Barc); 2016 Jun 19; 84(6):343-6. PubMed ID: 26724255
    [No Abstract] [Full Text] [Related]

  • 20. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
    de Fost M, van Noesel CJ, Aerts JM, Maas M, Pöll RG, Hollak CE.
    Haematologica; 2008 Jul 19; 93(7):1119-20. PubMed ID: 18519519
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.